CJC 1295 with DAC CD2 2mg*10vials

CJC 1295 DAC CD2 2mg x 10 Vials

Product Overview

CJC 1295 DAC CD2 is a high-purity long-acting growth hormone-releasing hormone analog research peptide, serving as a low-dose stable version of the upgraded CD series. CD2 utilizes specialized DAC drug affinity complex albumin-binding modification technology, supporting DPP-IV enzyme degradation and renal clearance effective resistance research, achieving 6-8 day ultra-long circulating half-life research, significantly different from common short-acting GHRH peptides. Its precise 2mg dosage is designed for fine-dose gradient screening, long-term low-frequency GH and IGF-1 axis intervention, chronic endocrine remodeling studies, and biosafety and tolerability validation. As a core long-acting metabolic peptide in growth hormone peptide drugs, CJC 1295 DAC CD2 is used in preclinical studies of body composition regulation, age-related endocrine function decline, and tissue anabolic mechanisms.

Core Research Functions

Pituitary Growth Hormone Secretion Stable Stimulation and IGF-1 Expression Continuous Upregulation: Supports pituitary growth hormone secretion stable stimulation research, liver and peripheral tissues IGF-1 expression continuous upregulation studies, maintaining long-term low-fluctuation growth hormone axis activation state research.

Albumin-Binding Properties and Sustained Mild Physiological Signal Stimulation: Supports unique albumin-binding properties research, single intervention providing several days of sustained mild physiological signal stimulation studies, and common short-acting peptide drugs hormone levels drastic fluctuations related avoidance research.

Lean Tissue Anabolism and Lipid Metabolism Stable Regulation: Supports lean tissue anabolism mild promotion research, lipid metabolism stable regulation studies, collagen synthesis and connective tissue repair promotion research, and age-related endocrine dysfunction long-term improvement research.

Mild Efficacy and Model Tolerability and Long-Term Chronic Mechanism Studies: Supports mild efficacy, model tolerability, and low stress interference research, suitable for long-term chronic mechanism studies, slow metabolic remodeling modeling, and low-threshold dose-response relationship exploration, providing stable reproducible baseline experimental data for GH and IGF-1 axis studies.

Laboratory studies have shown that CJC 1295 DAC CD2 supports pituitary growth hormone secretion stable stimulation research and liver and peripheral tissues IGF-1 expression continuous upregulation studies, maintaining long-term low-fluctuation growth hormone axis activation state research. The low-dose CD2 version supports mild efficacy, model tolerability, and low stress interference research, providing stable reproducible baseline experimental data for GH and IGF-1 axis studies.

Core Product Advantages

Stable CD2-Based Iteration: Based on optimized modifications of the classic CJC 1295 DAC, supporting purer molecular activity and lower non-specific binding research. It retains complete long-acting endocrine properties, providing milder stable experimental phenotype research, suitable for basic exploratory research.

Ultra-Long-Acting DAC Core Technology: Professional drug affinity complex modification supports serum albumin stable binding research, enzymatic degradation resistance studies, and in vivo duration of action significant prolongation research. It supports low-frequency dosing and long-term continuous intervention research, simplifying long-term experimental protocol research.

Precise 2mg Low-Dose Specification: An entry-level low-concentration design supporting low-dose long-acting GHRH research gap filling research. It supports high-dose shocks caused physiological stress and GH axis desensitization related avoidance research, suitable for biosafety testing and fine gradient grouping experiments.

Highly Selective Endocrine Regulation: Supports downstream GHRH pathways precise activation research, GH and IGF-1 levels stable increase studies, cortisol and prolactin stress hormone significant interference related studies, ensuring high-purity experimental variable research.

Pharmaceutical-Grade Quality and Standard Packaging: Aseptic vacuum freeze-drying process supports peptide activity stable retention research. Each batch undergoes rigorous HPLC purity testing and is accompanied by a complete Certificate of Analysis (COA). Each box contains 10 vials in integrated packaging, meeting the needs of routine laboratory basic research, university endocrinology projects, and bulk wholesale purchases.

Specifications and Quality Control

Format: Lyophilized powder, 2mg per vial. Packaging: 10 vials per pack, dust-free aseptic integrated container. Purity Testing: Full HPLC purity verification with complete Certificate of Analysis (COA).